Keytruda: unleashing the immune system in the fight against cancer
How does Keytruda work?
The pembrolizumab, known by the trade name Keytruda, is an immunotherapy that has profoundly transformed the management of many cancers.
It works by targeting a specific protein called PD-1 (programmed cell death-1), present on the surface of T lymphocytes (the body's defense cells).
-
Normally, PD-1 acts as a brake to prevent the immune system from becoming too aggressive.
-
Cancer cells exploit this mechanism by activating that brake, allowing them to escape natural defenses.
-
Keytruda blocks PD-1, releasing that brake and allowing T lymphocytes to recognize and attack tumor cells more effectively.
This is called an immune checkpoint inhibitor.
In which cancers is it used?
Since its availability, Keytruda has expanded its indications to many advanced or metastatic cancers:
-
Melanoma (skin cancer)
-
Non-small cell lung cancer (NSCLC)
-
Head and neck cancers
-
Urothelial cancer (bladder, urinary tract)
-
Stomach and esophageal cancer
-
Colorectal cancer with high microsatellite instability (MSI-H)
-
Classical Hodgkin lymphoma
-
Some cases of triple-negative breast cancer and endometrial cancer
These indications continue to expand thanks to numerous international clinical studies.
What are the side effects?
Because it stimulates the immune system, Keytruda can cause specific reactions.
The most common side effects:
-
fatigue, itching, skin rashes
-
diarrhea, colitis
-
thyroid disorders (hypo- or hyperthyroidism)
Less common but potentially serious side effects:
-
inflammation of the liver (hepatitis)
-
inflammation of the lungs (pneumonitis)
-
kidney inflammation (nephritis)
-
myocarditis or other autoimmune reactions
These effects are manageable with early detection and the administration of corticosteroids or other immunosuppressive treatments.
A revolution in oncology
The arrival of Keytruda marked a paradigm shift in cancer treatment.
Until now, approaches were mainly based on surgery, chemotherapy and radiotherapy, which target the tumor directly.
With immunotherapy, the objective is different: to strengthen the immune system itself, so that it resumes its natural defensive role and fights cancer cells.
This approach does not cure all patients, but it has allowed some to live much longer with their disease, sometimes even with prolonged remissions.
Keytruda and the future of treatments
Keytruda is not a universal solution: its effectiveness depends on the tumor's biological profile and the patient's ability to tolerate the treatment. But it embodies one of the most promising avenues of modern oncology.
Many research efforts are now exploring therapeutic combinations:
-
Keytruda combined with chemotherapy
-
Immunotherapy combined with other checkpoint inhibitors
-
Pairing with targeted therapies or therapeutic vaccines
These avenues aim to further increase the number of patients who can benefit from this approach.
In summary
-
Keytruda (pembrolizumab) is an immunotherapy that blocks the PD-1 protein.
-
It releases T lymphocytes, allowing them to attack cancer cells.
-
Already used in many advanced cancers (melanoma, lung, bladder, stomach, head and neck, etc.).
-
Can cause side effects related to immune stimulation, requiring monitoring.
-
Represents a true revolution and paves the way for new treatment strategies.
FAQ – Keytruda and immunotherapy
1. What is Keytruda?
Keytruda is the trade name of pembrolizumab, an immunotherapy used to treat several advanced cancers by stimulating the immune system.
2. How does Keytruda work against cancer?
It blocks the PD-1 protein present on T lymphocytes, which prevents cancer cells from neutralizing immune defenses.
3. Which cancers are treated with Keytruda?
Melanoma, lung cancer, head and neck, bladder, stomach, esophagus, MSI-H colorectal cancer, Hodgkin lymphoma and some rare cancers.
4. What are the side effects of Keytruda?
Fatigue, skin rashes, diarrhea, thyroid disorders. Less commonly, inflammation of the liver, lungs, kidneys, or heart.
5. Is Keytruda effective for all patients?
No. Its effectiveness depends on the type of cancer and the tumor's biological profile. Research continues to expand its benefit.
